Nasdaq
$0.5600▼ 1.82%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $150.2MShares out 2.700M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
6- 1d agoAfter-hours26.10.24 05:068-KKey event#●●●#●●●
Akebia Therapeutics, Inc.Bullish
Akebia Therapeutics received a deficiency notice from Nasdaq because its common stock closed below $1.00 for 30 consecutive business days, failing to meet the minimum bid price requirement. The company has 180 calendar days, until April 19, 2027, to regain compliance, which may involve measures such as a reverse stock split.…more
$0.5600-1.82%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.14Pre-market26.10.14 20:578-KKey event
Akebia Therapeutics, Inc.
Nicholas Grund, Senior Vice President and Chief Commercial Officer of Akebia Therapeutics, will resign from his position effective November 6, 2026, for personal reasons. Following his resignation, he has entered into a consulting agreement to provide advisory services to the company until April 30, 2027.…more
$0.5600-1.82%vs prev closeView filingShare - 8.10After-hours26.08.11 05:084Ownership
Akebia Therapeutics, Inc.
아키비아 테라퓨틱스(Akebia Therapeutics, Inc.)의 CEO인 존 버틀러(John P. Butler)가 2026년 8월 6일 자로 자사 주식에 대한 지분 변동을 신고하는 Form 4 공시를 제출하였습니다. 본 공시는 경영진의 실질적 지분 보유 현황 변경을 알리는 정기 보고입니다.…more
$0.5600-1.82%vs prev closeView filingShare
5 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.7Pre-market26.10.07 21:00#●●●#●●●
Akebia Therapeutics to Participate in Kidney Health Investor Forum
Akebia Therapeutics announced that its management team will participate in one-on-one meetings at the virtual U.S. Bancorp I BTIG Kidney Health Forum. The discussions will focus on the company's commercial products and its pipeline assets for rare kidney diseases.…more
$0.5600-1.82%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 10.1After-hours26.10.02 05:05
●●●●●●●● ●●●●● ●●●●●●
Akebia Therapeutics has granted stock options for 8,400 shares to a newly hired employee as an employment inducement. This is a standard compensation practice and does not have a material impact on the company's financial outlook.…more
$0.5600-1.82%vs prev close - 9.14Pre-market26.09.14 21:00
●●●●●●●● ●●●●● ●●●●●●
Akebia Therapeutics has initiated dosing for the first patient in its Phase 2 basket trial evaluating ebribafusp for rare kidney diseases. While initial data is expected in 2027, the trial is in early stages and does not provide immediate financial impact.…more
$0.5600-1.82%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report